Tallac Therapeutics’ Post

Sarcomas, the second most common type of solid tumor affecting children and adolescents, encompasses approximately 100 distinct subtypes, originating from diverse tissues such as bone and muscle. Conventional treatment approaches often fall short, particularly in cases diagnosed at advanced stages. But here's hope! We have pioneered the development of monoclonal antibodies (mAbs) and TCR-mimic antibodies for TCRm-T cell therapy aimed at treating sarcomas. These innovative therapies target either the tumor immune microenvironment or directly attack cancer cells. Download our NY-ESO-1/HLA-A02 poster to learn more: https://lnkd.in/erVTNJQY #SarcomaResearch #Immunotherapy #antibodylibrary #renbiologics #drugdiscovery #TumorResearch #antibodytherapeutics #cancerresearch #cancertherapy

Surjit Dixit and I thought of the concept to redirect endogenous cytokine separately. Now the concept is starting to demonstrate its potential in preclinical models, the advantages are becoming much clearer. 1. We don't need to dose a whopping amount of an engineered cytokine, which avoids systemic toxicity which is so common in the field 2. We use the natural cytokine so we do not encounter undesired side effects of engineering 3. We make relatively straightforward bi-specific antibodies and avoid a lot of the CMC headaches The concept is broad enough to cover many cytokines with desirable properties in oncology, auto-immune disease and metabolic disease. Thank you, BioCentury Inc., for this write up. https://lnkd.in/eA2s9gCK

evitria’s journal club - paper of the week no. 30 Bispecific antibody drug conjugates: Making 1+1>2 Yilin Gu et al. (2024) Bispecific antibody drug conjugates combine the strengths of ADCs and bispecific antibodies to address clinical challenges like poor internalization, off-target toxicity, and drug resistance. With ten BsADCs in clinical trials, this innovative approach shows promise in enhancing selectivity and internalization. However, further optimization is needed to fully realize their potential. BsADCs represent a significant advancement in the next generation of targeted cancer therapies – read this review to learn the latest! Developing bispecifics? Get in touch with our scientists to learn how we can support you: www.evitria.com/contact  #ADC #antibodies #CancerResearch #bispecificantibodies 

Plasmapheresis involves replacing plasma containing abnormal IgM with healthy plasma to help reduce IgM & hyperviscosity (when the blood becomes too thick). Proteasome inhibitors are treatments that block the action of proteasomes (cellular complexes that break down proteins) so that proteins can build up and kill the #WaldenstromsMacroglobulinemia (#WM) cells. Bruton’s tyrosine kinase (BTK) inhibitors are treatments that block the BTK protein, which WM cells need to grow and survive. These drugs can be taken in pill form. Monoclonal antibody therapy uses man-made antibodies engineered to target cancer cells. Learn more about treatments for WM and the upcoming #WMWorldAwarenessDay by visiting: https://lnkd.in/e3VK23rF

#VeryWorthwhileREADING: Tunable cell-expressor model system married with high throughput product profiling using #xCELLigence to help tackling "immune cold" modalities for low target expressing cell types. #onTargetoffTumor effect and #widerExpansion of your modality and pipeline.

Aberrant MYC pathway activation is found in cancer cells, while MYC-induced protein translation depends on GSPT1. Molecular glues targeting GSPT1 is identified as a potential treatment method in oncology. Monte Rosa’s MRT-2359 is an oral and selective molecular glue degrader of the translation termination factor GSPT1. The targeted GSPT1 degradation results in disrupting MYC-driven protein translation and reducing MYC-oncogenic signaling. MRT-2359 is in an ongoing phase 1/2 study in MYC-driven solid tumors with a current assessment of 0.75 mg dose level. The final phase 2 dose determination and updated clinical results are anticipated in the second half of 2024. MRT-2359 previously received Fast Track Designation in patients with previously treated, metastatic NSCLC with L-MYC or N-MYC expression, Orphan Drug Designation in small cell lung cancer (SCLC), and Fast Track Designation in previously treated, metastatic SCLC with L-MYC or N-MYC expression. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gPUBtAWY #MGD #MG #degrader #protein #degradation #TPD #GSPT1 #MYC #Tumors #Buildingblocks

Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the treatment of patients with platinum-resistant ovarian cancer. TUB-040 is a next-generation NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary P5 technology with superior biophysical properties that demonstrated effective and durable responses in a range of preclinical models, including ovarian cancer. The candidate is currently being evaluated in a multicenter Phase I/IIa study (NAPISTAR 1-01, NCT06303505) in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options. To learn more, read the press release here-https://hubs.ly/Q02DH8cM0 #ResearchNeverStops #TogetherForMedicinesThatMatter

Antibody drug conjugates (ADC) transform the precision medicine landscape, providing better drug targeting and efficacy through monoclonal antibody-based antigen recognition. While scientists have developed several ADC to use as cancer therapies, these compounds could also serve as inspiration to create drugs for other ailments, including the senescent cell accumulation associated with aging and age-related diseases. In this webinar, Salvador Macip will explain how he developed an ADC that selectively clears senescent cells. Register today: https://ow.ly/qE1a50Sa1HL

Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the treatment of patients with platinum-resistant ovarian cancer. TUB-040 is a next-generation NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary P5 technology with superior biophysical properties that demonstrated effective and durable responses in a range of preclinical models, including ovarian cancer. The candidate is currently being evaluated in a multicenter Phase I/IIa study (NAPISTAR 1-01, NCT06303505) in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC), who have exhausted other available treatment options. To learn more, read the press release here-https://hubs.ly/Q02DH3B70 #ResearchNeverStops #TogetherForMedicinesThatMatter